TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Rosen Law Firm
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

Rosen Law Firm is investigating a potential securities class action against aTyr Pharma regarding allegedly false statements about the efficacy of their drug Efzofitimod, with investors potentially suffering damages during the period of January 16, 2025 to September 12, 2025.

Insights
ATYR   negative

The lawsuit alleges the company disseminated false and misleading statements about their drug's capabilities, potentially causing investor damages, which indicates significant corporate governance and transparency issues